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Kidney-Specific Reduction of Oxidative
Phosphorylation Genes Derived from
Spontaneously Hypertensive Rat
Jason A. Collett*, Jiffin K. Paulose, Vincent M. Cassone, Jeffrey L. Osborn
Department of Biology, University of Kentucky, Lexington, KY, the United States of America
* jacollet@gmail.com
Abstract
Mitochondrial (Mt) dysfunction contributes to the pathophysiology of renal function and pro-
motes cardiovascular disease such as hypertension. We hypothesize that renal Mt-genes
derived from female spontaneously hypertensive rats (SHR) that exhibit hypertension have
reduced expression specific to kidney cortex. After breeding a female Okamoto-Aoki SHR
(SAP = 188mmHg) with Brown Norway (BN) males (SAP = 100 and 104 mmHg), hyperten-
sive female progeny were backcrossed with founder BN for 5 consecutive generations in
order to maintain the SHRmitochondrial genome in offspring that contain over increasing
BN nuclear genome. Mt-protein coding genes (13 total) and nuclear transcription factors
mediating Mt-gene transcription were evaluated in kidney, heart and liver of normotensive
(NT: n = 20) vs. hypertensive (HT: n = 20) BN/SHR-mtSHR using quantitative real-time PCR.
Kidney cortex, but not liver or heart Mt-gene expression was decreased ~2–5 fold in 12 of
13 protein encoding genes of HT BN/SHR-mtSHR. Kidney cortex but not liver mRNA expres-
sion of the nuclear transcription factors Tfam, NRF1, NRF2 and Pgc1α were also decreased
in HT BN/SHR-mtSHR. Kidney cortical tissue of HT BN/SHR-mtSHR exhibited lower cyto-
chrome oxidase histochemical staining, indicating a reduction in renal oxidative phosphory-
lation but not in liver or heart. These results support the hypothesis that renal cortex of rats
with SHR mitochondrial genome has specifically altered renal expression of genes encod-
ing mitochondrial proteins. This kidney-specific coordinated reduction of mitochondrial and
nuclear oxidative metabolism genes may be associated with heritable hypertension in SHR.
Introduction
Hypertension constitutes a primary and significant factor in the development of cardiovascular
disease. Despite major gains in the long-term treatment of hypertension, cardiovascular disease
remains the number one cause of death and disability in developed countries. Primary or
essential hypertension is regarded as a multi-factorial disease, influenced by both genetic inher-
itance and environmental conditions that influence gene expression. The genetic basis of
hypertension has been focused primarily on inheritance and expression of nuclear genes
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(nDNA) [1], despite the fact that mitochondria are present in multiple copies in each cell and
have their own genome. Oxidative phosphorylation (OXPHOS) depends on the coordinated
expression of two separate but interactive genomes, nuclear and mitochondrial. Numerous
trans-factors involved with mtDNA replication, transcription and mRNA processing are
nuclear encoded, including mtRNA polymerase, mtDNA polymerase, several regulatory tran-
scription factors and mtRNA processing proteins [2]. This nuclear-mitochondrial interaction
is essential to cellular health and function, and therefore may play a large role in the develop-
ment of or response to cardiovascular disease [3].
Mitochondrial dysfunction has been implicated in a wide variety of genetic disorders [4, 5],
and alterations in mitochondrial function have been observed in conjunction with aging and
development of hypertension in both rodents and humans [6–9]. Recently, mitochondrial
transfer RNA (tRNA) mutations were observed in a genetically focused population with a high
incidence of essential hypertension [10, 11]. Wilson et al. [12] have described a correlation
between a T4921C transition SNP, which lies in the mitochondrial tRNAlle gene (GenBank
accession no. NC_001807) and hypertension. The genetic association of mtDNA variants and
tRNA mutations [4] to type 2 diabetes and hypertension directly suggested mitochondrial dys-
function in the development of cardiovascular disease and metabolic syndrome [9]. Taken
together, there is growing evidence that altered mitochondrial gene expression may have a sig-
nificant role in the generation of cardiovascular disease phenotypes. The mechanisms by which
mitochondrial genes are expressed and regulated in disease remains unclear.
The impact of the kidney on long-term blood pressure regulation is well known. It has been
hypothesized that the “set-point” for the long-term control of BP resides in the kidney [13–15].
In this model, the set-point of the chronic renal function curve establishes the steady state rela-
tionship between renal perfusion pressure and urinary excretion of sodium and water, which
in turn affects blood volume and cardiac output. This renal-body fluid-pressure control system
exhibits “infinite feedback gain”, i.e., BP will stabilize only when intake and output of sodium
and water become exactly equal, which occurs at one pressure level for any given renal function
curve and salt intake level [16]. The importance of kidney function to modulate blood pressure
has been shown by Lifton et al. [17] demonstrating genetic variants in important renal path-
ways underlie all of the Mendelian disorders affecting blood pressure homeostasis. These stud-
ies postulated that altered renal expression of genes may contribute significantly to the disease.
The goal of the present study was to determine the renal expression of mitochondrial protein-
encoding genes and the nuclear genes known to regulate their expression, in a unique rat strain
with localized mt-DNA from Okomoto-Aoki SHR. The “conplastic” strain was developed by
crossing a hypertensive female Spontaneously Hypertensive Rat (SHR) with normotensive,
male Brown Norway (BN) rats (BN/SHR-mtSHR) [18]. Hypertensive female offspring were
then phenotypically selected and crossed with founder males for several generations. All off-
spring had identical mitochondrial DNA (mtDNA) of the progenitor SHR, barring any muta-
tion. The results of these studies document significant reduced expression of renal mtRNA and
nuclear encoded regulatory elements in hypertensive male and female offspring. These studies
suggest that specifically reduced renal cortical mtRNA expression may lead to decreased
OXPHOS in rats with isolated mitochondrial SHR genomes and hypertension.
Materials and Methods
Experimental Animals
All experiments were carried out in strict accordance with the recommendations provided in
the AAALAC Guide to the Care and Use of Laboratory Animals and the National Institutes of
Health. All protocols in this study were specifically approved by the University of Kentucky
Kidney Mitochondrial Gene Expression and Hypertension
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Institutional Animal Care and Use Committee (IACUC #000649L2003). All surgeries were
performed following complete anesthesia of individual animals. Tissue collection for these
studies also was conducted under full anesthesia. At the time of any change in protocol (minor
or major) amendments were submitted to the IACUC and approved prior to conducting any
individual experiment. Since this was a long term breeding study, the original IACUC approval
served for a significant time period. All individual studies for this protocol approval were
reevaluated at 3 year intervals as required by AAALAC standards. A “conplastic” colony using
phenotypic selection was employed. The development and phenotypic characterization have
been described in detail elsewhere [18]. The Aoki-Okamoto SHR/Brown Norway (BN/SHR)
rat colony was developed by breeding a female SHR (Charles River Labs, Wilmington, MA)
with 2 different normotensive Brown Norway males (BN and BN^, respectively; Charles
River Labs, Wilmington, MA). Beginning at 10 weeks of age, rats were phenotyped using tail
cuff plethysmography (Kent Scientific, Torrington, CT). Each individual animal was trained
and acclimated to the tail cuff device prior to measuring blood pressure. In these training ses-
sions all animals were covered and remained in the dark to provide the type of comfort that
behaviorally meets the needs of rats. Following blood pressure determinations, the most hyper-
tensive female offspring were then back-crossed to the original progenitor BN males for 5 sub-
sequent generations. Animals were monitored daily for health and evaluated for normal
behavioral activity.
After repeated blood pressure recordings that assured consistent determination of arterial
pressure, rats not scheduled for rebreeding were euthanized with an overdose of sodium pento-
barbital (60 mg/kg i.p), decapitated, and organ tissues were rapidly frozen in acetone super-
cooled on dry ice and stored for later analysis.
Measurement of arterial pressure
Systolic arterial pressure (SAP) was evaluated in parents and offspring beginning no earlier
than 10–12 weeks of age. Phenotypes were assigned as either normotensive (NT:
SAP 124mmHg), borderline hypertensive (BHT: 125 SAP149 mmHg) or hypertensive
(HT: SAP 150mmHg; Fig 1). To minimize stress and improve reliability of BP measure-
ments, several steps were used in the BP recording method that has been previously character-
ized and published [19, 20]. Rats were exposed and acclimated to the measurement procedures
and restraint equipment prior to BP recordings. A dark cover was placed over the restrained
animal for the duration of the BP measurement, and BP recordings were performed at the
same time each day. All equipments were thoroughly cleaned and disinfected before and after
each individual rat to eliminate foreign scent. Animals were moderately warmed to dilate the
ventral artery. Arterial pressures were derived from the average results of5 measurements in
each recording session. The average BP of5 separate recording sessions with<5% variability
was used to establish the phenotype of each animal. Both systolic and diastolic pressures were
obtained and recorded. For purposes of reporting, the systolic pressures were used for the
determination of the specific individual phenotype. NT (blue) and HT (red) age and sex-
matched BN/SHR-mtSHR rats (11 female/10 male per group) were utilized for the current study
(Fig 1). There was no significant difference in BP between male and female NT rats or male
and female HT rats (p>0.05).
RNA Extraction and RT-PCR
Renal cortex, liver and left ventricular cardiac tissue were selected from age and sex-matched
HT and NT BN/SHR-mtSHR rats (n = 20 NT; n = 20 HT) as described above. Total RNA
was extracted with Trizol reagent (Invitrogen, Carlsbad, CA) and purified using RNeasy
Kidney Mitochondrial Gene Expression and Hypertension
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Fig 1. Six generations of BN/SHR-mtSHR rats with corresponding average systolic pressure (SAP) values. Three distinct populations persisted
throughout all 6 generations, with hypertension being dominantly expressed and maintained despite the reduction of the SHR nuclear genome. Tissues from
HT animals used in all genome analysis experiments (both mitochondrial and nuclear) are indicated by the red circles. Tissues used from NT animals are
indicated by the blue circles (adapted from Collett et. al.; 10).
doi:10.1371/journal.pone.0136441.g001
Kidney Mitochondrial Gene Expression and Hypertension
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minicolumns (Qiagen Inc., Valencia, CA) according to the manufacturer’s protocol. Possible
genomic DNA was digested with DNase I (Qiagen Inc., Valencia, CA). Concentration and purity
of all RNA samples was determined by the Nanodrop ND-1000 spectrophotometer (Nanodrop
Technologies, Wilmington, DE). Extracted RNA was reverse-transcribed into complementary
DNA (cDNA) using qScript cDNA Supermix (Quanta Biosciences, Gaithersburg, MD) in a total
volume of 20μl using a MyCyler Thermal Cycler (Bio-Rad Laboratories, Hercules, CA).
Quantitative Real-Time PCR
Quantitative Real-Time PCR was performed on a StepOnePlus Real-time PCR system (Applied
Biosystems, Foster City, CA). Real-time quantitative PCR amplifications were performed in
triplicate on a 96-well plate. Pre-designed TaqMan primers and hydrolysis probes for all genes
of interest were purchased from Applied Biosystems (mt-ND1- Rn03296764_s1,mt-ND2-
Rn03296765_s1,mt-ND3- Rn03296825_s1,mt-ND4- Rn03296781_s1,mt-ND4L- Rn03296792_s1,
mt-ND5- Rn03296799_s1,mt-ND6- Rn03296815_s1,mt-CO1- Rn03296721_s1,mt-CO2-
Rn03296737_s1,mt-CO3- Rn03296820_s1,mt-CYB- Rn03296746_s1,mt-ATP6- Rn03296710_s1,
mt-ATP8- Rn03296716_s1,NRF1- Rn01455958_m1,NRF2a- Rn01767215_m1,NRF2b-
Rn01514289_g1, Pgc1α-Rn00598552_m1, Tfam-Rn00580051_m1, Cyc1-Rn01504159_g1, Cox6c-
Rn00820983_gH, GAPDH- Rn01775763_g1). Primers and probes were verified as operating at
similar efficiencies. Target gene and endogenous control amplicons were labeled with either FAM
or VIC. The levels of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression were mea-
sured in all samples to normalize gene expression for sample-to-sample differences in RNA input,
RNA quality and reverse transcription efficiency. Each sample was analyzed in triplicate, and the
expression was calculated according to the 2−ΔΔCt method [21, 22].
Citrate Synthase Assay
Citrate synthase activity was determined in homogenates prepared from kidney tissue using a
citrate synthase assay kit (CS0720; Sigma-Aldrich, St. Louis, MO) [23]. Total muscle protein
was determined in triplicate by the method of Bradford [24] and the protein concentration of
all samples was equalized. Citrate synthase activity was determined based on the formation of
2-nitro-5-thiobenzoic acid at a wavelength of 412 nm at 25°C on a microplate absorbance
reader (iMark; BIO RAD, Hercules, CA). In each well, 8 μl of sample was added to a reaction
medium containing 178 μl of assay buffer, 2 μl of 30 mmol/L acetyl coenzyme A, and 10 mmol/
L 2-nitro-5-thiobenzoic acid. The baseline solution absorbance was recorded, reactions were
initiated by the addition of 10 μl of oxaloacetic acid, and the change in absorbance measured
every 15 seconds for 2 minutes.
Cytochrome Oxidase Histochemistry
Cytochrome oxidase (CO) activity was determined in fresh frozen sections (20μm) in kidney,
liver and heart tissue, as described previously [25]. Briefly, fresh frozen tissue was sectioned on
a cryostat at 20 μm. Slides were immersed in 0.5% glutaraldehyde in 0.1% phosphate buffer for
5 minutes. Slides were then incubated for 2 hours in the same diaminobenzidene (DAB)/cyto-
chrome c solution simultaneously (preceded by 5 minutes of sparged oxygen) at 37°C. Slides
were then postfixed in 10% formalin for 15 minutes. Finally, slides were immersed in a serious
of ethanol dehydration steps: 50, 70, 90, 95, 100% ethanol (30 seconds each) and xylene (2
changes, 5 minutes each). Slides were then coverslipped using Histomount (Life Technologies)
and dried overnight. Colorometric change was used as a direct measurement of metabolic
activity, in which darker color indicated higher metabolically active tissue. Relative density per
area was calculated using ImageJ (NIH).
Kidney Mitochondrial Gene Expression and Hypertension
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Data analysis
Blood pressures and citrate synthase activity among animals were initially analyzed by 1-way
analysis of variance (ANOVA) followed by post-hoc comparisons using the Bonferroni t-test.
Tissue mRNA expression levels were analyzed using Mann-Whitney U Test comparisons. The
0.05 level of probability was utilized as the minimum criterion of significance. All statistical
analyses were performed using GraphPad Prism 4.0 (GraphPad Software, Inc., La Jolla, CA).
Results and Discussion
Evaluation of mt-gene expression
Multiple mtDNA encoded genes of the mitochondrial respiratory chain were significantly
reduced in renal, but not liver or cardiac tissue of HT BN/SHR-mtSHR, including five complex
I, one complex III, three complex IV and both subunits of ATP synthase. Additionally, the
nuclear trans-factors Tfam, NRF1, NRF2a, NRF2b and Pgc1a were all downregulated in the kid-
ney, but not elsewhere, of HT BN/SHR-mtSHR.
Complex I: NADH dehydrogenase. The renal expression of five of the seven mt-encoded
genes of complex I were significantly reduced in hypertensive versus normotensive BN/SHR-
mtSHR.mt-ND1 was reduced ~3.7 fold in HT BN/SHR-mtSHR (P = 0.0317). mt-ND3 was
reduced ~2.6 fold in HT SHR/BN-mtSHR (P = 0.0077).mt-ND4 was reduced ~10.8 fold in HT
SHR/BN-mtSHR (P = 0.0221).mt-ND4L was reduced ~7.7 fold in HT SHR/BN-mtSHR
(P = 0.05).mt-ND5 was reduced ~2.7 fold in HT SHR/BN-mtSHR (P = 0.00167).mt-ND6 was
reduced ~1.7 fold in HT SHR/BN-mtSHR (P = 0.0822) (Fig 2A).mt-ND2 was not different
between the two phenotypes (P = 0.5994).
Complex 3: Cytochrome bc1 complex. The renal mtRNA expression of mt-encoded cyto-
chrome b (mt-CYB) was significantly reduced in hypertensive versus NT BN/SHR-mtSHR.mt-
CYB was reduced ~5 fold in HT BN/SHR-mtSHR (P = 0.0103) (Fig 2B).
Complex 4: Cytochrome C oxidase. All three mt-encoded genes of complex IV were sig-
nificantly reduced in hypertensive versus normotensive BN/SHR-mtSHR.mt-CO1 was reduced
~3.2 fold in HT BN/SHR-mtSHR (P = 0.0164),mt-CO2 was reduced ~3.6 fold in HT BN/SHR-
mtSHR (P = 0.0063), andmt-CO3 was reduced 4.1 fold in HT BN/SHR-mtSHR (P = 0.0085) (Fig
2C).
Complex V: ATP synthase. Two of the sixteen genes that encode vital proteins for ATP
synthase of the electron transport chain are mt-encoded.mt-ATP6 was reduced ~2.3 fold in
HT BN/SHR—mtSHR (P<0.05), whilemt-ATP8 was reduced ~3.1 fold in HT BN/SHR-mtSHR
(P = 0.0255) (Fig 2D).
Tissue expression in Liver and Heart. Expression levels of several mt-genes were evalu-
ated in both the liver and heart of HT and NT BN/SHR-mtSHR as described above.mt-CYB,
mt-CO2 andmt-ND1,mt-ATP6 were shown to be not different (P>0.05) between the HT and
NT BN/SHR-mtSHR liver or heart tissues. This is in contrast to renal tissue wherein each of
these genes exhibited reduced expression in HT vs. NT animals (Fig 3). Further, complex 1
mRNA expression was evaluated for each subunit in heart tissue, and there was no difference
in mRNA expression between NT and HT animals (p>0.0.5) (S1 Fig).
Evaluating Mitochondrial Function: Cytochrome Oxidase Activity
CO activity was measured densitometrically in kidney, liver and heart sections (20μm) in NT
(n = 6) and HT (n = 6) BN/SHR-mtSHR. CO activity was significantly reduced (P = 0.0269) in
the kidney, but not the liver or heart (P>0.05) in HT BN/SHR-mtSHR (Fig 4).
Kidney Mitochondrial Gene Expression and Hypertension
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Fig 2. Quantitative Real-Time PCRmt-genes across 4 complexes of ETC. A:mt-ND1was reduced ~3.7 fold in HT BN/SHR-mtSHR (*P<0.05). mt-ND3
was reduced ~2.6 fold in HT SHR/BN-mtSHR (**P<0.01).mt-ND4was reduced ~10.8 fold in HT SHR/BN-mtSHR (*P<0.05).mt-ND4Lwas reduced ~7.7 fold
in HT SHR/BN-mtSHR (P<0.05).mt-ND5was reduced ~2.7 fold in HT SHR/BN-mtSHR (P<0.05).mt-ND6was reduced ~1.7 fold in HT SHR/BN-mtSHR
(P>0.05) (Fig 1A).mt-ND2was not different between the two phenotypes (P>0.05).B:mt-CYBwas reduced ~5 fold in HT BN/SHR-mtSHR (*P<0.05).C:mt-
CO1was reduced ~3.2 fold in HT BN/SHR-mtSHR (*P<0.05),mt-CO2was reduced ~3.6 fold in HT BN/SHR-mtSHR (P<0.05), andmt-CO3was reduced 4.1
Kidney Mitochondrial Gene Expression and Hypertension
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Evaluation of Nuclear Genome Trans-Regulatory Factors
Peroxisome proliferator-activated receptor gamma co-activator 1-alpha(PGC-1α).
PGC-1α regulates NRF-dependent transcription, increases expression of both mitochondrial
fold in HT BN/SHR-mtSHR (P<0.05).D:mt-ATP6was reduced ~2.3 fold in HT BN/SHR—mtSHR (*P<0.05), whilemt-ATP8was reduced ~3.1 fold in HT BN/
SHR-mtSHR (*P<0.05). (NT: open bars; HT: closed bars).
doi:10.1371/journal.pone.0136441.g002
Fig 3. Quantitative Real-Time PCR of representative mt-genes of complex I-V were evaluated in liver and heart tissue of HT and NT BN/SHR-mtSHR.
A:mt-CYB, B:mt-CO2, C:mt-ND1, andD: ATP6 were shown to be not different (P>0.05) between the HT and NT BN/SHR-mtSHR liver and heart compared
with kidney tissue. (NT: open bars; HT: closed bars).
doi:10.1371/journal.pone.0136441.g003
Kidney Mitochondrial Gene Expression and Hypertension
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and nuclear encoded genes of oxidative phosphorylation and induces mitochondrial biogene-
sis. HT BN/SHR-mtSHR exhibited ~2.5 fold reduction in PGC-1αmRNA in kidney tissue com-
pared with NT BN/SHR-mtSHR (P = 0.0098) (Fig 5A).
Nuclear Respiratory Factors. Nuclear respiratory factors 1 and 2 are well characterized
transcriptional activators of genes involved in assembly of the respiratory apparatus, as well as
constituents of the mtDNA transcription and replication machinery [26]. A main factor
involved in mtDNA transcription is Tfam, whose expression is regulated by NRF1. All three
NRFs were reduced in the kidney, but not liver of HT compared to NT BN/SHR-mtSHR. Renal
NRF1mRNA expression was reduced ~1.8 fold in HT BN/SHR-mtSHR compared with NT BN/
SHR-mtSHR (P = 0.0307) (Fig 5B). Renal NRF2amRNA expression was reduced ~2.3 fold in
HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (P = 0.0083) (Fig 5C). Renal NRF2b
Fig 4. Cytochrome oxidase staining was significantly reduced in the kidney of HT vs. NT BN/SHR-mtSHR (P<0.05). However, CO activity was not
different in liver (p = 0.3828) or heart (p = 0.6664) of HT vs. NT BN/SHR-mtSHR. (NT: open bars; HT: closed bars).
doi:10.1371/journal.pone.0136441.g004
Kidney Mitochondrial Gene Expression and Hypertension
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mRNA expression was reduced ~1.9 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-
mtSHR (P = 0.0377) (Fig 5D).
Mitochondrial Transcription Factor A (Tfam). Tfam is a key activator of mammalian
mitochondrial transcription. Kidney, but not liver exhibited reduced TfammRNA expression
~2.5 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (P = 0.0281) (Fig 5E).
Nuclear-encoded mitochondrial genes: Cytochrome C-1 (Cyc1), cytochrome c oxidase,
subunit Vic (Cox6c). In order to assess the downstream pathways of the nuclear encoded
regulatory elements, nuclear-encoded mitochondrial gene expression were assessed. There was
no difference in the renal mRNA expression of CYC or Cox6c between NT (n = 10) and HT
(n = 10) BN/SHR-mtSHR (P>0.05) (Fig 6).
Fig 5. Quantitative Real-Time PCR graphs of the well-established nuclear-mitochondrial induction of mitochondrial gene transcription. A.
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α). Renal PGC-1αmRNA expression was reduced ~2.5 fold in HT BN/SHR-
mtSHR compared with NT BN/SHR-mtSHR (P<0.05). B. Nuclear Respiration Factor (NRF) 1. RenalNRF1mRNA expression was reduced ~1.8 fold in HT BN/
SHR-mtSHR compared with NT BN/SHR-mtSHR (P<0.05). C. Nuclear Respiration Factor 2A. RenalNRF2AmRNA expression was reduced ~2.3 fold in HT
BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (P<0.05). D. Nuclear Respiration Factor 2B. RenalNR2BmRNA expression was reduced ~1.9 fold in HT
BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (P<0.05). E.Mitochondrial Transcription Factor A (Tfam). Renal TfammRNA expression was reduced
~2.5 fold in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (P<0.05) Expression levels were not different in the liver (P>0.05) in HT BN/SHR-mtSHR
compared with NT BN/SHR-mtSHR for any of the transcription factors. (NT: open bars; HT: closed bars).
doi:10.1371/journal.pone.0136441.g005
Kidney Mitochondrial Gene Expression and Hypertension
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Evaluating Mitochondrial Number: Citrate Synthase Assay. To quantify mitochondrial
number, citrate synthase activity was measured in kidney homogenates of NT (n = 10) and HT
(n = 10) BN/SHR-mtSHR (Fig 7). There was no difference between the two phenotypes
(P = 0.9676), indicating that mitochondrial number was not driving the reduced transcript
expression in HT BN/SHR-mtSHR kidneys.
Discussion
There is significant evidence the mitochondria, variations in the mitochondrial genome and in
mitochondrial function may be associated with the progression of arterial hypertension [5, 7, 8,
Fig 6. Quantitative Real-Time PCR of nuclear-encodedmitochondrial genes.Neither renalA:
Cytochrome C-1 (Cyc1) (P = 0.3928) nor B: cytochrome c oxidase, subunit Vic (Cox6c)(P = 0.7618) were
different between NT and HT BN/SHR-mtSHR. (NT: open bars; HT: closed bars).
doi:10.1371/journal.pone.0136441.g006
Fig 7. Citrate synthase activity was not different in renal tissue of NT versus HT BN/SHR-mtSHR.Mitochondrial number was not different between the
two phenotypes (P = 0.9676). (NT: open bars; HT: closed bars).
doi:10.1371/journal.pone.0136441.g007
Kidney Mitochondrial Gene Expression and Hypertension
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11, 27–29]. Of particular interest is the nature of mitochondrial inheritance, being strictly
maternal, and of female origin. The results of the current study provide evidence that gene
expression in renal cortical mitochondrial genes encoding respiratory chain complexes is
downregulated in hypertensive rats stemming from a SHR/BN conplastic-breeding paradigm.
This breeding method provided a continuous passing of the maternal SHR mitochondrial
genome, while mixing the inherited nuclear genome between the maternal SHR and paternal
BN with each succeeding generation. We have reported the maintenance of arterial systolic
hypertension for 6 consecutive generations despite the reduction in the maternally derived
nuclear genome (Fig 1) [18]. Results from the current study show mitochondrial protein-cod-
ing genes critical for OXPHOS exhibited significantly reduced expression in kidney cortex, but
not in the liver or heart, in HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR (Figs 2 and
3). In HT BN/SHR-mtSHR, nuclear genes involved in mitochondrial biogenesis and transcrip-
tion (PGC-1α, NRF1, NRF2a/b, Tfam), also exhibited reduced expression in kidney cortex, but
not liver, compared with NT BN/SHR-mtSHR (Fig 5). Thus, in hypertensive rats with SHR
mitochondrial genome but minimal SHR nuclear genome, there is kidney-specific reduction in
expression of both mitochondrial and nuclear genes critical to OXPHOS.
The viability of individual electron transport chain (ETC) subunits and the potential for dis-
ease has been previously evaluated [28, 30]. Lopez-Campistrous et al. [28] reported that defects
in complex I in the brainstem of SHR increased reactive oxygen species production, decreased
ATP synthesis and impaired respiration in hypertension. We report here that reduced expres-
sion of the mt-genes coding for complex I, which may potentially reduce complex I function.
Altered function of complex III, a major site of superoxide formation and reactive oxygen spe-
cies (ROS) production, may play an important role in renal mitochondrial ETC dysfunction.
Das et al. [31] reported that the regulation of ATP synthase is abnormal in SHR cardiac cells,
as demonstrated by the inability to respond to acute increases in energy demand compared to
cells from normotensive rats. Data from our study indicate that mt-gene expression is reduced
in kidneys, a key organ in blood pressure control. To evaluate mitochondrial function, we mea-
sured cytochrome oxidase histochemical staining in NT and HT BN/SHR-mtSHR. Cytochrome
oxidase serves as an endogenous metabolic marker. As shown in Fig 4, CO staining was signifi-
cantly reduced in the kidney cortex, but not in liver or heart of HT BN/SHR-mtSHR. Thus, oxi-
dative phosphorylation may be reduced in the kidneys of HT BN/SHR-mtSHR which is
consistent with the renal cortical-specific downregulation of mitochondrial gene expression.
Taken together, the altered function of ETC subunits derived from decreased kidney cortex-
specific mt-gene expression may have several implications to the progression of hypertension.
Data presented here poses the important and critical question: Does the reduction of renal
mitochondrial gene expression and function contribute significantly to the etiology of hyper-
tension? Or does hypertension cause the downregulation of mitochondrial gene transcription
and function? Recently, Lee et al. [32] postulated that increased mitochondrial activity in prox-
imal convoluted tubule cells of young, normotensive SHR may contribute to the development
of hypertension at adulthood. These studies show that various parameters of mitochondrial
activity were elevated in very young SHR prior to the onset of hypertension, while mt-gene
expression remained unchanged. Our study documents mitochondrial genes encoding proteins
of each mitochondrial subunit of mRNA were reduced in renal tissue of HT BN/SHR-mtSHR
compared with NT BN/SHR-mtSHR. It is possible that mitochondrial activity is elevated in
renal proximal tubules of very young SHR prior to the onset of hypertension. As the develop-
ment of hypertension progresses in the maturing SHR, renal mitochondrial gene expression
may then decline as a compensatory mechanism to, for instance, decrease sodium transport
along various segments of the nephron. This is plausible, as altered renal sodium handling and
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renal function are a hallmark of hypertension. Ongoing and future studies are being conducted
to address this possible relationship and mechanism specific to the SHR.
One of the more interesting aspects of this study is a potential ETC dysfunction driven by
transcript differences in the kidneys, but not in other tissues, of mt-genes and the nuclear
trans-factors that regulate them. As shown in Fig 4, CO histochemical staining was signifi-
cantly reduced in the kidneys, but not liver or heart of HT BN/SHR-mtSHR, hence, it appears
that mitochondrial function was decreased in the kidneys of HT BN/SHR-mtSHR. Altered renal
function has been well recognized as a key factor in the development and maintenance of
hypertension [13, 16, 33–38]. One such mechanism that may be responsible is altered regula-
tion of the renin-angiotensin system (RAS). The interactions among RAS and altered mito-
chondrial function has been advanced recently by Benigni et al. [39] Deletion of the Agtr1a
gene resulted in the reduced age-related cardio-renal complications, improved mitochondrial
biogenesis, and increased longevity in mice. Treatment with antioxidants, mitochondrial
superoxide dismutase mimetics, and AT1r blockers decreased vascular O2
.- production and
attenuated development of hypertension in SHR [40, 41]. In this regard, we have previously
shown that renal cortex of HT BN/SHR-mtSHR exhibit elevated AT1r mRNA (Agtr1a) expres-
sion compared to NT BN/SHR-mtSHR, while the renal and systemic expression of renin, angio-
tensinogen, and angiotensin-converting enzymes were not different [18]. Renal cortex of HT
BN/SHR-mtSHR also had elevated AT1r protein compared with NT BN/SHR-mt
SHR, and this
increase was positively correlated with elevated systolic BP [18]. De Cavanagh et al. [27] dem-
onstrated that oxidative stress is associated with mitochondrial dysfunction in SHR, and that
this dysfunction is attenuated with AT1r blockade with Losartan. These data support the
hypothesis that hypertensive phenotype derived from the SHR is driving the reduced mito-
chondrial gene expression, which may lead to decreased OXPHOS.
PGC-1α plays a central role in regulating mitochondrial content and function within cells,
because of its ability to co-activate and augment several promoters of nuclear-encoded mito-
chondrial genes, as well as regulating mitochondrial transcription via the NRF-Tfam pathway
[42]. PGC-1α regulates NRF-dependent transcription, increases expression of both mitochon-
drial and nuclear encoded genes of oxidative phosphorylation and induces mitochondrial bio-
genesis [43]. It has been shown that metabolic functions are controlled by PGC-1α in a tissue
specific manner in brown fat, muscle and liver [44], however kidney regulation of PGC-1α and
its effectors is unknown. Results from this study show a coordinated reduction of the kidney-
specific expression of nuclear and mitochondrial genes vital to OXPHOS in hypertensive BN/
SHR-mtSHR, which may play a significant role in the development and maintenance of hyper-
tension (Fig 8).
In order to further assess the downstream pathways of the nuclear-encoded regulatory ele-
ments, the expressions of two separate nuclear-encoded mitochondrial genes were assessed.
Other nuclear-encoded mitochondrial genes known to be regulated by the PGC-1α-NRF-Tfam
pathway were not different. Neither kidney Cytochrome C-1 (Cyc1) nor cytochrome c oxidase
subunit Vic (Cox6c) were differentially expressed in kidney cortex of HT and NT BN/SHR-
mtSHR (Fig 6). This suggests that the biogenesis and transcription of mitochondrial genes,
known to be regulated by the PGC-1α pathway, may be regulated in a more complex manner
than previously thought. Mitochondrial gene expression also appears to be regulated in a tis-
sue-specific manner. If this is the case, our data suggests that tissues of high metabolic activity
such as the kidney, may have a critical role in the development of—or response to—
hypertension.
Whenever mitochondrial disturbances inhibit electron transport, electrons are forwarded
into an increased generation of ROS [9]. Increased mitochondrial ROS is linked to metabolic
diseases such as aging, diabetes and hypertension [45–47]. Mitochondria are a major site of
Kidney Mitochondrial Gene Expression and Hypertension
PLOS ONE | DOI:10.1371/journal.pone.0136441 August 26, 2015 14 / 19
oxygen consumption and oxidative stress due to generation of ROS, where complexes I and III
are the main sites of mitochondrial superoxide formation [48]. Recently, mitochondrial ETC
dysfunction has been shown to directly cause oxidative stress during hypertension [6]. Ballin-
ger et al. [49] have demonstrated that reactive oxygen species decreased mtRNA transcripts,
mitochondrial protein synthesis and reduced cellular ATP levels. Taken together, ROS
decreases OXPHOS, and decreased OXPHOS increases ROS, both of which contribute to
hypertension.
Conclusion
In summary, we present novel data documenting a decrease in a well-defined nDNA-mtDNA
interactive pathway resulting in decreased mtDNA transcripts of proteins vital to OXPHOS in
renal cortex. This potential coordinated reduction of nuclear-mitochondrial OXPHOS genes
and its association with hypertension until now was largely unexplored (Fig 8). Though the
exact mechanisms driving this reduction in gene expression is currently not known, it is clear
that reduced mt-gene expression in the kidney coincides with hypertension in adult BN/SHR-
mtSHR. Using our current model, where the nuclear genome is increasingly BN while maintain-
ing the SHR mitochondrial genome, in combination with other similar models, the relevance
of the specific control of each of these genomes and how they may contribute to disease may be
Fig 8. Hypothetical nuclear-mitochondrial pathway driving reducedmtDNA transcription, ultimately leading to elevated arterial pressure and
hypertension. The pathway is clearly reduced in the kidney, but not liver of HT BN/SHR-mtSHR compared with NT BN/SHR-mtSHR.
doi:10.1371/journal.pone.0136441.g008
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revealed. Furthermore, the nuclear-mitochondrial gene expression interactions may be criti-
cally important in the manifestation of the renal disease process and progression of
hypertension.
Supporting Information
S1 Fig. Quantitative Real-Time PCR of representative mt-genes of complex I were evalu-
ated in heart tissue of HT and NT BN/SHR-mtSHR.None of the 7 mitochondrial encoded
genes of complex 1 exhibited gene expression differences (P>0.05) between the HT and NT
BN/SHR-mtSHR (NT: open bars; HT: closed bars).
(TIF)
S2 Fig. Quantitative Real-Time PCR of superoxide dismutases. Neither renal A: Superoxide
dismutase 1 (SOD1) nor B: superoxide dismutase 2 (SOD2) were different (P>0.05) between
NT and HT BN/SHR-mtSHR (NT: open bars; HT: closed bars).
(TIF)
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